Home > Insider Trading > Filing (0001181431-13-056831)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1338042	Aegerion Pharmaceuticals Inc.	AEGR	Pharmaceutical Preparations (2834)	202960116

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1213040	J. Martha Carter	C/O Aegerion Pharmaceuticals, Inc. 101 Main Street, Suite 1850 Cambridge MA 02142	Chief Regulatory Officer & Svp	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2013-11-01	5,000	$14.84	6,500	No	4	M	Direct
Common Stock	Disposition	2013-11-01	5,000	$82.81	1,500	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Disposition	2013-11-01	5,000	$0.00	5,000	$14.84

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
127,000		2021-03-01	No	4	M	Direct

Footnotes

The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.8101 to $82.812, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
88,000 of the shares of common stock underlying this stock option vest in equal monthly installments over a four-year period commencing immediately upon the date of grant, March 1, 2011; and 44,000 of the shares underlying this stock option began to vest monthly in equal installments over a four-year period commencing upon the later to occur of the submission of the New Drug Application for lomitapide to the U.S. Food and Drug Administration and the submission of the Marketing Authorisation Application for lomitapide to the European Medicines Agency.